Key Points
-
Highlights the clinical outcomes of patients prescribed bisphosphonates following dento-alveolar procedures.
-
Assesses the parameters and risks of developing a bisphosphonate-related osteonecrosis of the jaws (BRONJ).
-
Compares the risk factors of developing a BRONJ to previously published data.
Abstract
Aim The aim of this retrospective study was to examine the outcome of patients referred to a dedicated clinic for dental extractions while they were prescribed either oral or intra-venous (IV) bisphosphonates (BPs). The following parameters were assessed: mode of BP administration, indication for BP prescription, incidence of BRONJ, concomitant risk factors for development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) and demographic details.
Material and methods The clinical records of 225 patients who underwent dental extraction while receiving oral or intravenous bisphosphonates were reviewed. Their clinical outcome, specifically the development of BRONJ was determined.
Results Of the 225 patients, 202 were prescribed oral and 23 IV BPs. 34.8% (8/23) of patients prescribed IV BPs developed BRONJ following dental extraction, which was a significantly (p <0.001) higher proportion than that of the oral BP group, which was 2.5% (5/202 patients). 12.3% (8/65) patients taking BPs with steroids were at a significantly increased risk of a BRONJ (p <0.003). 12.3% (7/57) males developed a BRONJ compared with 3.6% (6/168) females where p = 0.015. All of the patients who developed a BRONJ as a result of oral BP prescription had been taking this medication for three years or more.
Conclusion In our patient cohort the risk of developing a BRONJ following dental extractions was greatest in those patients receiving IV BPs and those on oral BPs with concomitant steroid medication.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Assael L A . Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and oreventative strategies. J Oral Maxillofac Surg 2009; 67(Suppl 5): 35–43.
Marx R E . Pamidronate (Aredia) and zoledronate (Zometa) induced vascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117.
Ruggiero S L, Dodson T B, Assael L A et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg 2009; 67(Suppl 5): 2–12.
Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaws: a report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479–1491.
Lo J C, O'Ryan F S, Gordon N P et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243–253.
Rogers S N, Hung J, Barber A J, Lowe D . A survey of consultant members of the British Association of Oral and Maxillofacial Surgeons regarding bisphosphonate-induced osteonecrosis of the jaws. Br J Oral Maxillofac Surg 2009; 47: 598–601.
Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415–423.
Dodson T B . Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 44–52.
Madrid C, Bouferrache K, Abarca M, Jaques B, Broome M . Bisphosphonate-related osteonecrosis of the jaws: how to manage cancer patients. Oral Oncol 2010; 46: 468–470.
Wessel J H, Dodson T B, Zavras A I . Zoledronate, Smoking and obesity are strong risk factors for osteonecrosis of the jaws: a case-control study. J Oral Maxillofac Surg 2008; 66: 625–631.
Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945–952.
Jadu F, Lee L, Pharoah M, Reece D, Wang L . A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015–2019.
Chiu C T, Chiang W F, Chuang C Y, Chang S W . Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw - a serial case analysis. J Oral Maxillofac Surg 2010; 68: 1055–1063.
Oliver R . Bisphosphonates and oral surgery. Oral Surg 2009; 2: 56–53.
Kos M, Kuebler J F, Luczak K, Engelke W . Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010; 38: 255–259.
Sedghizadeh P P, Kumar S K, Gorur A, Schaudinn C, Shuler C F, Costerton J W . Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66: 767–775.
Sarasquete M E, González M, San Miguel J F, GarcÃa-Sanz R . Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009; 15: 382–387.
McLeod N M, Patel V, Kusanale A, Rogers S N, Brennan P A . Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg 2011; 49: 335–342.
Author information
Authors and Affiliations
Corresponding author
Additional information
Refereed Paper
Rights and permissions
About this article
Cite this article
Taylor, T., Bryant, C. & Popat, S. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital. Br Dent J 214, E18 (2013). https://doi.org/10.1038/sj.bdj.2013.327
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bdj.2013.327
This article is cited by
-
Electron microscopic analysis of necrotic bone and failed implant surface in a patient with medication-related osteonecrosis of the jaw
Maxillofacial Plastic and Reconstructive Surgery (2023)
-
Efficacy of hyaluronic acid, absorbable collagen sponge, and their combination in minimizing bisphosphonate-related osteonecrosis of the jaws (BRONJ) after dental extraction: a preliminary animal histomorphometric study
Maxillofacial Plastic and Reconstructive Surgery (2022)
-
Considerations for restorative dentistry secondary care referrals - part 1: defining strategic importance
British Dental Journal (2022)
-
Significance of medication discontinuation on bisphosphonate-related jaw osteonecrosis in a rat model
Scientific Reports (2022)
-
The incidence of medication-related osteonecrosis of the jaw following tooth extraction in patients prescribed oral bisphosphonates
British Dental Journal (2021)
